|
Media Releases |
Financial Reports |
Presen-tations |
|
07/26/2006
|
 |
|
|
| Lonza continues to deliver: 17% increase in performance and decision taken to build out the Singapore Biopharmaceutical plant EBIT increased in the first half of 2006 by 17% to CHF 158 million. Lonza
continues to successfully execute critical milestones in the long-term
strategic plan.
|
Overview Sales in the first half of 2006 rose 15.5%, totaling CHF 1 415 million; almost half of this growth was due to the rise in raw material price. Net income growth increased at a slower pace than EBIT in the first half of 2006 at 10.3%, due to higher one-time financing cost, and is expected to be on EBIT growth level by year end. Four hundred new colleagues joined the Lonza team in the first half year, to drive the implementation of our ambitious growth strategy.
For detailed information please view the attached PDF file |
|
|
